In vitro susceptibility of vancomycin-resistant enterococci (VRE) to fosfomycin

Mary Beth Perri; Ellie Hershberger; Mihaela Ionescu; Carl Lauter; Marcus J Zervos

doi:10.1016/s0732-8893(02)00370-x

In vitro susceptibility of vancomycin-resistant enterococci (VRE) to fosfomycin

Diagn Microbiol Infect Dis. 2002 Apr;42(4):269-71. doi: 10.1016/s0732-8893(02)00370-x.

Authors

Mary Beth Perri¹, Ellie Hershberger, Mihaela Ionescu, Carl Lauter, Marcus J Zervos

Affiliation

¹ Department of Medicine, Section of Infectious Diseases, William Beaumont Hospital, Royal Oak, MI, USA.

PMID: 12007445
DOI: 10.1016/s0732-8893(02)00370-x

Abstract

We evaluated the in vitro activity of fosfomycin against 75 clinical isolates of vancomycin-resistant enterococci (VRE). Using the NCCLS breakpoint for susceptibility of urinary tract isolates to fosfomycin (MIC > or = 256), 51 out of 52 Enterococcus faecium and all Enterococcus faecalis isolates tested were susceptible or intermediate to fosfomycin.

MeSH terms

Anti-Bacterial Agents / pharmacology*
Enterococcus faecalis / drug effects*
Enterococcus faecalis / isolation & purification
Enterococcus faecium / drug effects*
Enterococcus faecium / isolation & purification
Fosfomycin / pharmacology*
Humans
Microbial Sensitivity Tests
Vancomycin Resistance*

Substances

Anti-Bacterial Agents
Fosfomycin